8 completed, 3 not yet recruiting, 2 terminated, 2 unknown. 16 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 16 | Completed 8, Not yet recruiting 3, Terminated 2, Unknown 2, Recruiting 1 |
| Phase 1 | 1 | Completed 1 |
Follow Orlistat: new trials by email Literature Review of Orlistat trials Research Report on Orlistat
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Orlistat Plus Progestin for Fertility-Sparing Treatment of Endometrial Cancer or Atypical Hyperplasia Orlistat, Progestin - Endometrial Neoplasms, Endometrial Cancer | Phase 2 | Not yet recruiting | Peking University People's Hospital | 48 | 2026-07-01 | 2026-07-20 |
| A Trial With EMP16 in Preparation for Late Phase Studies EMP16-02 120 mg orlistat/40 mg acarbose, AlliĀ® 60 mg, Vi-SiblinĀ® S - Overweight or Obese, Obesity and Overweight | Phase 2 | Not yet recruiting | Empros Pharma AB | 39 | 2025-05-20 | 2025-05-28 |
| Orlistat Overcoming Third-generation EGFR-TKI Resistance Orlistat 120 mg - Lung Adenocarcinoma, Osimertinib | Phase 2 | Not yet recruiting | Ping Peng | 36 | 2025-02-16 | 2025-02-12 |
| Long Term Efficacy and Safety of Orlistat for Type 1 Hyperlipoproteinemia Orlistat, Placebo - Type 1 Hyperlipoprotenemia | Phase 2 | Recruiting | University of Texas Southwestern Medical Center | 28 | 2024-01-26 | 2026-07-21 |
| Study Exploring the Supportive Effect of Acarbose in Weight Management EMP16-120/40, MR orlistat 120 mg, Conventional orlistat 120 mg, - Overweight or Obesity | Phase 2 | Unknown | Empros Pharma AB | 320 | 2023-04-18 | 2024-02-20 |
| Orlistat for the Treatment of Type I Hyperlipoproteinemia Orlistat - Hyperlipoproteinemia Type I, Hypertriglyceridemia | Phase 2 | Completed | University of Texas Southwestern Medical Center | 2 | 2015-12-01 | 2023-02-08 |
| Phase 2 Study of Orlistat and SLx-4090 for the Treatment of Type 1 Hyperlipoproteinemia SLx-4090 placebo, Orlistat Placebo, Orlistat - Type 1 Hyperlipoproteinemia | Phase 2 | Terminated | University of Texas Southwestern Medical Center | 5 | 2015-11-01 | 2021-08-19 |
| Ketogenic Diet Treatment of Obesity With Co-morbid Type 2 Diabetes Mellitus and/or Obstructive Sleep Apnea Ketogenic diet, Orlistat, Standardized diet - Obesity, Diabetes | Phase 2 | Unknown | Mid-Atlantic Epilepsy and Sleep Center, LLC | 150 | 2014-01-01 | 2018-08-17 |
| Drug Therapy Induced Weight Loss to Improve Blood Vessel Function in Subjects With Obesity Metformin, Orlistat, Topiramate - Obesity, Metabolic Syndrome X | Phase 2 | Terminated | University of Iowa | 128 | 2011-03-01 | 2026-03-12 |
| Double-Blind, Multi-Center, Randomized Study to Assess the Efficacy and Safety of Velneperit (S-2367) and Orlistat Administered Individually or Combined With a Reduced Calorie Diet (RCD) in Obese Subjects Velneperit 400 mg, Orlistat 120 mg, Orlistat Placebo - Obesity | Phase 2 | Completed | Shionogi | 486 | 2010-04-01 | 2018-05-09 |
| Metformin Versus Orlistat in Obese Polycystic Ovary Syndrome (PCOS) Patients orlistat - Obesity | Phase 2 | Completed | Yazd Research & Clinical Center for Infertility | 80 | 2008-12-01 | 2021-04-01 |
| Treatment of Hyperandrogenism Versus Insulin Resistance in Infertile Polycystic Ovary Syndrome (PCOS) Women Orlistat/Meal Replacement/Lifestyle Modification, Loestrin 1/20, Combination of treatments - Polycystic Ovary Syndrome | Phase 2 | Completed | Milton S. Hershey Medical Center | 217 | 2008-09-01 | 2016-11-07 |
| The Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes liraglutide, orlistat, placebo - Metabolism and Nutrition Disorder, Obesity | Phase 2 | Completed | Novo Nordisk A/S | 564 | 2007-01-10 | 2017-11-01 |
| Efficacy and Safety of ATL-962 in Obese Diabetics ATL-962, Orlistat - Non-Insulin-Dependent Diabetes Mellitus, Obesity | Phase 2 | Completed | Alizyme | 600 | 2004-12-01 | 2006-08-29 |
| Development of Rational Ways of Medical and Non-medical Treatment Methods for Metabolic Syndrome Xenical, Pionorm, Diroton, Diltiazem, Atorvastatin, "Analimentary detoxication" - Metabolic Syndrome | Phase 1 / Phase 2 | Completed | Nazarbayev University | 351 | 2003-01-01 | 2015-11-30 |
| Safety and Efficacy of Xenical in Children and Adolescents With Obesity-Related Diseases Orlistat, Placebo - Diabetes Mellitus, Hypertension | Phase 2 | Completed | Jack Yanovski | 200 | 1998-05-01 | 2012-12-18 |
Obesity (9) · Diabetes Mellitus (3) · Hypertension (3) · Overweight (3) · Diabetes Mellitus, Type 2 (2) · Dyslipidemias (2) · Hypertriglyceridemia (2) · Metabolic Syndrome (2) · Polycystic Ovary Syndrome (2) · Adenocarcinoma of Lung (1) · Endometrial Hyperplasia (1) · Endometrial Neoplasms (1) · Familial hyperchylomicronemia syndrome (1) · Glucose Intolerance (1) · Hyperlipoproteinemia Type I (1)
University of Texas Southwestern Medical Center (3) · Empros Pharma AB (2) · Alizyme (1) · Jack Yanovski (1) · Mid-Atlantic Epilepsy and Sleep Center, LLC (1) · Milton S. Hershey Medical Center (1) · Nazarbayev University (1) · Novo Nordisk A/S (1) · Peking University People's Hospital (1) · Ping Peng (1) · Shionogi (1) · University of Iowa (1) · Yazd Research & Clinical Center for Infertility (1)
United States (8) · Sweden (3) · Denmark (2) · Finland (2) · Netherlands (2) · United Kingdom (2) · Belgium (1) · China (1) · Czechia (1) · Iran (1) · Kazakhstan (1) · Spain (1)
Abhimanyu Garg, MD (2) · Abbas Aflatoonian, Professor (1) · Abhimanyu G Garg, MD (1) · Chandna Vasandani, Ph.D (1) · Christos Coutifaris, M.D., Ph.D. (1) · Gary L Pierce, PhD (1) · Helena Litorp, MD, PhD (1) · Jack A Yanovski, M.D. (1) · Pavel Klein, M.D. (1) · Peter Kopelman (1) · Richard S Legro, M.D. (1) · Tabynbayev Nariman, Professor (1)
PMID 12105286, PMID 12126214, PMID 15112907, PMID 19461584, PMID 19853906, PMID 21844879, PMID 22140269, PMID 23942319, PMID 26210388, PMID 26401593, PMID 27172435, PMID 27253669, PMID 28163748, PMID 28386912, PMID 28473337, PMID 28950422, PMID 29659879, PMID 29718281, PMID 32968804, PMID 33059389, PMID 33059886, PMID 39952695, PMID 41349930